Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-19
    E.g., 2018-10-19

Archive Search

2 results
12:00 AM, Jun 20, 2011  |  BC Week In Review | Clinical News  |  Clinical Status

PT001: Phase II started

Atrovent ipratropium HFA inhalation aerosol in about 100 patients. Boehringer Ingelheim GmbH (Ingelheim, Germany) markets Atrovent HFA
12:00 AM, Nov 22, 2004  |  BC Week In Review | Clinical News  |  Regulatory

Atrovent HFA regulatory update

FDA approved Atrovent HFA inhalation aerosol, a reformulation of Atrovent (CFC), for bronchospasm associated with chronic obstructive …
disease (COPD), including chronic bronchitis and emphysema. Boehringer Ingelheim Corp. , Ridgefield, Conn.   Product: Atrovent HFA